Effects of preceding interferon therapy on outcome after surgery for hepatitis C virus-related hepatocellular carcinoma

Journal of Surgical Oncology

Volumn 102, Issue 4, 2010, Pages 308-314

  Tomimaru, Yoshito ^a   Nagano, Hiroaki ^a   Eguchi, Hidetoshi ^a   Kobayashi, Shogo ^a   Marubashi, Shigeru ^a   Wada, Hiroshi ^a   Tanemura, Masahiro ^a   Umeshita, Koji ^b   Hiramatsu, Naoki ^b   Takehara, Tetsuo ^b   Doki, Yuichiro ^a   Mori, Masaki ^a  

^a OSAKA UNIVERSITY   (Japan)

^b OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Hepatic resection; Hepatitis C virus (HCV); Hepatocellular carcinoma (HCC); Interferon (IFN)

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; INTERFERON;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CANCER SURGERY; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE FREE INTERVAL; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER RESECTION; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; AGED; ALANINE TRANSAMINASE; ASPARTATE AMINOTRANSFERASES; CARCINOMA, HEPATOCELLULAR; FEMALE; HEPATITIS C; HUMANS; INTERFERONS; LIVER NEOPLASMS; MALE; MIDDLE AGED; SURVIVAL RATE;

EID: 77956588097     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.21633     Document Type: Article

References (37)

1. Shiratori Y, Shiina S, Imamura M, et al.: Characteristic difference of hepatocellular carcinoma between hepatitis B- and C- viral infection in Japan. Hepatology 1995;22:1027-1033.
2. Tsukuma H, Hiyama T, Tanaka S, et al.: Risk factors for hepatocellular carcinoma among patients with chronic liver disease. N Engl J Med 1993;328:1797-1801. (Pubitemid 23174709)
3. Kumada T, Nakano S, Takeda I, et al.: Patterns of recurrence after initial treatment in patients with small hepatocellular carcinoma. Hepatology 1997;25:87-92.
4. Shimada M, Takenaka K, Gion T, et al.: Prognosis of recurrent hepatocellular carcinoma: A 10-year surgical experience in Japan. Gastroenterology 1996;111:720-726.
5. Davis GL, Balart LA, Schiff ER, et al.: Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial. Hepatitis Interventional Therapy Group. N Engl J Med 1989;321:1501-1506.
6. Hagiwara H, Hayashi N, Mita E, et al.: Detection of hepatitis C virus RNA in serum of patients with chronic hepatitis C treated with interferon-alpha. Hepatology 1992;15:37-41.
7. Kasahara A, Hayashi N, Mochizuki K, et al.: Risk factors for hepatocellular carcinoma and its incidence after interferon treatment in patients with chronic hepatitis C. Osaka Liver Disease Study Group. Hepatology 1998;27:1394-1402.
8. Nishiguchi S, Kuroki T, Nakatani S, et al.: Randomised trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet 1995;346:1051-1055.
9. Effect of interferon-alpha on progression of cirrhosis to hepatocellular carcinoma: A retrospective cohort study. International Interferon-alpha Hepatocellular Carcinoma Study Group. Lancet 1998;351:1535-1539.
10. Nishiguchi S, Shiomi S, Nakatani S, et al.: Prevention of hepatocellular carcinoma in patients with chronic active hepatitis C and cirrhosis. Lancet 2001;357:196-197.
11. Ikeda K, Saitoh S, Arase Y, et al.: Effect of interferon therapy on hepatocellular carcinogenesis in patients with chronic hepatitis type C: A long-term observation study of 1,643 patients using statistical bias correction with proportional hazard analysis. Hepatology 1999;29:1124-1130.
12. Imai Y, Kawata S, Tamura S, et al.: Relation of interferon therapy and hepatocellular carcinoma in patients with chronic hepatitis C. Osaka Hepatocellular Carcinoma Prevention Study Group. Ann Intern Med 1998;129:94-99.
13. Ikeda M, Fujiyama S, Tanaka M, et al.: Clinical features of hepatocellular carcinoma that occur after sustained virological response to interferon for chronic hepatitis C. J Gastroenterol Hepatol 2006;21:122-128.
14. Makiyama A, Itoh Y, Kasahara A, et al.: Characteristics of patients with chronic hepatitis C who develop hepatocellular carcinoma after a sustained response to interferon therapy. Cancer 2004;101:1616-1622.
15. Uenishi T, Kubo S, Hirohashi K, et al.: Relationship between response to previous interferon therapy and postoperative recurrence of hepatitis C virus-related hepatocellular carcinoma. Hepatol Res 2002;24:404-412. (Pubitemid 36002130)
16. Uenishi T, Nishiguchi S, Tamori A, et al.: Influence of interferon therapy on outcome after surgery for hepatitis C virus-related hepatocellular carcinoma. Hepatol Res 2006;36:195-200.
17. Liver Cancer Study Group of Japan. General rules for the clinical and pathological study of primary liver cancer (in Japanese), 5th edition. Tokyo: Kanehara; 2008.
18. Edmondson HA, Steiner PE: Primary carcinoma of the liver: A study of 100 cases among 48,900 necropsies. Cancer 1954;7: 462-503.
19. Sakon M, Umeshita K, Nagano H, et al.: Clinical significance of hepatic resection in hepatocellular carcinoma: Analysis by disease-free survival curves. Arch Surg 2000;135:1456-1459.
20. Tarao K, Rino Y, Ohkawa S, et al.: Close association between high serum alanine aminotransferase levels and multicentric hepatocarcinogenesis in patients with hepatitis C virus-associated cirrhosis. Cancer 2002;94:1787-1795.
21. Yamanaka N, Takada M, Tanaka T, et al.: Viral serostatus and coexisting inflammatory activity affect metachronous carcinogenesis after hepatectomy for hepatocellular carcinoma. A further report. J Gastroenterol 2000;35:206-213.
22. Harada H, Kitagawa M, Tanaka N, et al.: Anti-oncogenic and oncogenic potentials of interferon regulatory factors-1 and -2. Science 1993;259:971-974.
23. Lai CL, Lau JY, Wu PC, et al.: Recombinant interferon-alpha in inoperable hepatocellular carcinoma: A randomized controlled trial. Hepatology 1993;17:389-394.
24. Liedtke C, Groger N, Manns MP, et al.: Interferon-alpha enhances TRAIL-mediated apoptosis by up-regulating caspase-8 transcription in human hepatoma cells. J Hepatol 2006;44:342-349.
25. Eguchi H, Nagano H, Yamamoto H, et al.: Augmentation of antitumor activity of 5-fluorouracil by interferon alpha is associated with up-regulation of p27Kip1 in human hepatocellular carcinoma cells. Clin Cancer Res 2000;6:2881-2890.
26. Ota H, Nagano H, Sakon M, et al.: A case of successful treatment of advanced hepatocellular carcinoma with tumor thrombi in the major portal branches and inferior vena cava with combined intraarterial 5-fluorouracil, adriamycin and cisplatin therapy. Gan To Kagaku Ryoho 2003;30:1673-1677.
27. Sakon M, Nagano H, Dono K, et al.: Combined intraarterial 5-fluorouracil and subcutaneous interferon-alpha therapy for advanced hepatocellular carcinoma with tumor thrombi in the major portal branches. Cancer 2002;94:435-442. (Pubitemid 34081374)
28. Nagano H, Miyamoto A, Wada H, et al.: Interferon-alpha and 5-fluorouracil combination therapy after palliative hepatic resection in patients with advanced hepatocellular carcinoma, portal venous tumor thrombus in the major trunk, and multiple nodules. Cancer 2007;110:2493-2501.
29. Nagano H, Sakon M, Eguchi H, et al.: Hepatic resection followed by IFN-alpha and 5-FU for advanced hepatocellular carcinoma with tumor thrombus in the major portal branch. Hepatogastroenterology 2007;54:172-179.
30. Nakamura M, Nagano H, Sakon M, et al.: Role of the Fas/FasL pathway in combination therapy with interferon-alpha and fluorouracil against hepatocellular carcinoma in vitro. J Hepatol 2007;46:77-88.
31. Wada H, Nagano H, Yamamoto H, et al.: Combination therapy of interferon-alpha and 5-fluorouracil inhibits tumor angiogenesis in human hepatocellular carcinoma cells by regulating vascular endothelial growth factor and angiopoietins. Oncol Rep 2007;18:801-809.
32. Yamamoto T, Nagano H, Sakon M, et al.: Partial contribution of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)/TRAIL receptor pathway to antitumor effects of interferon-alpha/5-fluorouracil against hepatocellular carcinoma. Clin Cancer Res 2004;10:7884-7895.
33. Ikeda K, Arase Y, Saitoh S, et al.: Interferon beta prevents recurrence of hepatocellular carcinoma after complete resection or ablation of the primary tumor-A prospective randomized study of hepatitis C virus-related liver cancer. Hepatology 2000;32:228-232.
34. Shiratori Y, Shiina S, Teratani T, et al.: Interferon therapy after tumor ablation improves prognosis in patients with hepatocellular carcinoma associated with hepatitis C virus. Ann Intern Med 2003;138:299-306.
35. Nishiguchi S, Tamori A, Kubo S: Effect of long-term post-operative interferon therapy on intrahepatic recurrence and survival rate after resection of hepatitis C virus-related hepatocellular carcinoma. Intervirology 2005;48:71-75.
36. Kubo S, Nishiguchi S, Hirohashi K, et al.: Effects of long-term postoperative interferon-alpha therapy on intrahepatic recurrence after resection of hepatitis C virus-related hepatocellular carcinoma. A randomized, controlled trial. Ann Intern Med 2001;134:963-967. (Pubitemid 32466235)
37. Kubo S, Nishiguchi S, Hirohashi K, et al.: Randomized clinical trial of long-term outcome after resection of hepatitis C virus-related hepatocellular carcinoma by postoperative interferon therapy. Br J Surg 2002;89:418-422. (Pubitemid 34595504)